LifeVantage Co. (NASDAQ:LFVN) Director Sells $161,200.00 in Stock

LifeVantage Co. (NASDAQ:LFVN) Director Raymond B. Greer sold 8,000 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $20.15, for a total value of $161,200.00. Following the transaction, the director now owns 99,288 shares of the company’s stock, valued at approximately $2,000,653.20. This represents a 7.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

LifeVantage Trading Up 0.7 %

NASDAQ:LFVN opened at $18.56 on Friday. The firm has a market cap of $232.95 million, a PE ratio of 33.14 and a beta of 0.84. The stock has a fifty day moving average price of $19.70 and a 200 day moving average price of $14.13. LifeVantage Co. has a 12-month low of $5.22 and a 12-month high of $27.38.

LifeVantage (NASDAQ:LFVN) last released its earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.08. LifeVantage had a return on equity of 34.29% and a net margin of 3.46%.

LifeVantage Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Investors of record on Monday, March 3rd will be issued a $0.04 dividend. The ex-dividend date is Monday, March 3rd. This represents a $0.16 dividend on an annualized basis and a yield of 0.86%. LifeVantage’s dividend payout ratio (DPR) is presently 28.57%.

Analyst Ratings Changes

Several research analysts have recently commented on LFVN shares. Lake Street Capital started coverage on LifeVantage in a research report on Thursday, December 19th. They set a “buy” rating and a $26.00 price target for the company. Craig Hallum started coverage on LifeVantage in a research report on Tuesday, January 14th. They set a “buy” rating and a $35.00 price target for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Copeland Capital Management LLC purchased a new stake in LifeVantage during the 4th quarter worth about $65,000. Hillsdale Investment Management Inc. lifted its holdings in LifeVantage by 7.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock worth $258,000 after buying an additional 1,000 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in LifeVantage during the 4th quarter worth about $282,000. Ritholtz Wealth Management lifted its holdings in LifeVantage by 62.0% during the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock worth $346,000 after buying an additional 10,974 shares during the last quarter. Finally, Barclays PLC lifted its holdings in LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after buying an additional 11,608 shares during the last quarter. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.